Pharmacy World and Science

, Volume 27, Issue 5, pp 371–375 | Cite as

Using Imipenem and Cilastatin During Continuous Renal Replacement Therapy

  • Alison CottonEmail author
  • Bryony  Dean Franklin
  • Stephen Brett
  • Alison Holmes
Review Article


Aim: To identify and review studies which have sought to define the pharmacokinetics of imipenem and cilastatin in patients receiving continuous renal replacement therapy (CRRT).

Method: Literature was primarily identified using Pharmline, Embase and Medline databases using the search terms ‘imipenem,’ ‘haemofiltration,’ ‘haemodialysis’ and ‘pharmacokinetics.’ Papers that discussed only intermittent haemodialysis were excluded.

Results: Seven papers were identified which described the pharmacokinetics of imipenem in patients receiving CRRT. Four different modes of CRRT were used. The methods of sampling, dosages used and assumptions made during pharmacokinetic calculations varied widely between the studies. Total body clearance of imipenem during CRRT in patients suffering from acute renal failure was found to range between 89 and 149 ml/min. Total body clearance of cilastatin ranged between 9 and 32 ml/min. Total body clearance of both imipenem and cilastatin was reduced in patients with chronic renal failure. Total body clearance of cilastatin was also reduced by impaired liver function. Dose recommendations made ranged between 500 mg 6-hourly and 500 mg 12-hourly.

Conclusions: The heterogeneity of the studies identified prevents them being analysed as a single group. For meaningful dosage recommendations to be made, further studies are required using larger populations and with more detail regarding liver dysfunction and duration of renal failure.


Acute kidney failure Cilastatin Clearance CRRT Haemodialysis Haemofiltration Imipenem Pharmacokinetics 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Norrby, SR, Alestig, K, Ferber, F, Huber, JL, Jones, KH, Kahan, FM,  et al. 1983aPharmacokinetics and tolerance of N-formimidoyl thienamycin (MK0787) in humansAntimicrob Agents Chemother232939Google Scholar
  2. 2.
    Norrby, SR, Alestig, K, Björnegård, B, Burman, LA, Ferber, F, Huber, JL,  et al. 1983bUrinary recovery of N-formimidoyl thienamycin (MK0787) as affected by co-administration of of N-formimidoyl thienamycin dihydropeptidase inhibitorAntimicrob Agents Chemother233007Google Scholar
  3. 3.
    AHFS Drug Information. Bethesda: American Society of Health-System Pharmacists Inc., 2003. ISBN 1-58528-039-9Google Scholar
  4. 4.
    Rogers, JD, Meisinger, MAL, Ferber, F, Calendra, GB, Demetriades, JL, Bland, JA 1985Pharmacokinetics of imipenem/ cilastatin in volunteersRev Infec Dis7S43546Google Scholar
  5. 5.
    Drussano, GL, Standiford, HC 1985Pharmacokinetic profile of imipenem/cilastatin in normal volunteersAm J Med784753Google Scholar
  6. 6.
    British National Formulary 46. London: British Medical Association & Royal Pharmaceutical Society Great Britain, Sept 2003. ISBN 0-85369-556-3Google Scholar
  7. 7.
    Kellum, JA, Johnson, JP, Kramer, D,  et al. 1998Diffusive versus convective treatment: effects on mediators of inflammation in patients with severe systemic inflammatory response syndromeCrit Care Med2619952000PubMedGoogle Scholar
  8. 8.
    Tegeder, I, Bremer, F, Oelkers, R, Schobel, H, Schüttler, J, Brune, K,  et al. 1997Pharmacokinetics of imipenem–cilastatin in critically ill patients undergoing continuous venovenous hemofiltrationAntimicrob Agents Chemother4126405PubMedGoogle Scholar
  9. 9.
    Mueller, B, Scarim, SK, Macias, WL 1993Comparison of imipenem pharmacokinetics in patients with acute or chronic renal failure treated with continuous hemofiltrationAm J Kidney Dis211729PubMedGoogle Scholar
  10. 10.
    Hashimoto S, Honda M, Yamaguchi M, Sekimoto M, Tanaka Y. Pharmacokinetics of imipenem and cilastatin during continuous venovenous hemodialysis in patients who are critically iII. ASAIO J 1997; 84–8.Google Scholar
  11. 11.
    Vos, MC, Vincent, HH, Yzerman, EPF 1992Clearance of imipenem/cilastatin in acute renal failure patients treated by continuous hemodiafiltration (CAVHD)Intensive Care Med182825CrossRefPubMedGoogle Scholar
  12. 12.
    Keller, E, Fecht, H, Böhler, J, Schollmeyer, P 1989Single-dose kinetics of imipenem/cilastatin during continuous arteriovenous haemofiltration in intensive care patientsNephrol Dial Transplant46405PubMedGoogle Scholar
  13. 13.
    Przechera, M, Bengel, D, Rider, T 1991Pharmacokinetics of imipenem/cilastatin during continuous arteriovenous hemofiltrationContrib Nephrol931314PubMedGoogle Scholar
  14. 14.
    Dehne, MG, Kroh, UR 1995lmipenem/cilastin dosage during acute renal fialure and hemofiltrationIntensive Care Med21863CrossRefPubMedGoogle Scholar
  15. 15.
    Kihara, M, Ikeda, Y, Shibata, K, Masumori, S, Ebira, H, Shiratori, K,  et al. 1994Clin Nephrol4219397PubMedGoogle Scholar
  16. 16.
    Reeves DS. Human pharmacokinetics of N-formimidoylthienamycin alone and in combination with a dehydropeptidase inhibitor (MK-701) and probenecid. Proc 13th Int Congress Chemother 30–33Google Scholar
  17. 17.
    Gibson, TP 1986Renal disease and drug metabolism: an overviewAm J Kidney Dis8717PubMedGoogle Scholar

Copyright information

© Springer 2005

Authors and Affiliations

  • Alison Cotton
    • 1
    Email author
  • Bryony  Dean Franklin
    • 2
  • Stephen Brett
    • 3
  • Alison Holmes
    • 4
  1. 1.Pharmacy Department Hammersmith Hospital NHS TrustLondonUK
  2. 2.Academic Pharmacy UnitHammersmith Hospitals NHS Trust/School of Pharmacy, University of LondonLondonUK
  3. 3.Department of Intensive Care MedicineHammersmith Hospitals NHS TrustLondonUK
  4. 4.Department of Infectious DiseasesImperial College/Hammersmith Hospitals NHS TrustLondonUK

Personalised recommendations